Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 2/20 | 0.44 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 5/20 | 0.35 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13316657 | 0.90 | MRGPRX4 (0.39) | METTL3MRGPRX4KLKB1CMA1 | |
| SCHEMBL3618515 | 0.86 | METTL3 (0.44) | METTL3MRGPRX4KLKB1CMA1NOTUM | |
| SCHEMBL3628451 | 0.84 | METTL3 (0.42) | METTL3MRGPRX4KLKB1CMA1NOTUM | |
| SCHEMBL3623481 | 0.82 | METTL3 (0.41) | METTL3KLKB1CMA1NOTUM | |
| SCHEMBL3624155 | 0.82 | METTL3 (0.42) | METTL3MRGPRX4CMA1NOTUM | |
| SCHEMBL3623800 | 0.81 | METTL3 (0.41) | METTL3KLKB1CMA1NOTUM | |
| SCHEMBL3625003 | 0.81 | METTL3 (0.41) | METTL3CMA1NOTUM | |
| SCHEMBL3625696 | 0.81 | METTL3 (0.44) | METTL3CMA1NOTUM | |
| SCHEMBL3624017 | 0.81 | METTL3 (0.43) | METTL3KLKB1 | |
| SCHEMBL13316686 | 0.81 | METTL3 (0.40) | METTL3MRGPRX4CMA1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | claimed |
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-04-20 | — | — | US | claimed |
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | NQO2, ACE, CDK20 | METTL3 3971/4885CLCN2 3567/4885MRGPRX4 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.